Concomitant intraductal carcinoma of the prostate and response to hormonal therapy in metastatic prostate carcinoma

CONCLUSIONS: IDC-P seems to be a subtype of prostate cancer that is associated with a shorter response to hormonal treatment when compared to acinar adenocarcinoma in metastatic patients. New drugs in CRPC scenario as abiraterone and enzalutamide also obtained less response in IDC-P patients. In daily clinical practice it might be interesting to take into account that patients with IDC-P may present shorter responses to first and second line hormonal treatments.PMID:33712315 | DOI:10.1016/j.acuro.2020.06.017

Source: Actas Urologicas Espanolas - March 13, 2021 Category: Urology & Nephrology Authors: J M Abascal-Junquera L Fumad ó-Ciutat B Gasa-Galmes M Costa-Planells M Munarriz-Polo A Sanrom à-Salvà L Polaina-Barroso C Sol à-Marqués N Juanpere-Rodero J Lloreta-Trull L Cecchini-Rosell Source Type: research